Literature DB >> 25563712

Systemic or local thrombolysis in high-risk pulmonary embolism.

Liviu Macovei1, Razvan Mihai Presura, Catalina Arsenescu Georgescu.   

Abstract

BACKGROUND AND AIM: High-risk pulmonary embolism (PE) represents an important health problem in emergency cardiology, being associated with a high rate of mortality. The aim of this study is to assess the efficacy and safety of pulmonary intra-arterial thrombolysis with streptokinase compared to systemic thrombolysis. METHODS AND
RESULTS: In our study, 28 patients with acute high risk PE were treated by intra-arterial thrombolysis with clinical success rate of 96.4%, while in the group with systemic thrombolysis (24 patients) the rate of clinical success was significantly lower (70.8%). Also, pressure gradient between right ventricle (RV) and right atrial (RA) (PRV-RA) decreased significantly in patients treated by pulmonary intra-arterial thrombolysis instead of systemic thrombolysis. Mortality during the hospitalization was 0% in the group with local thrombolysis and 29.2% in the other group, with a significant statistical difference. Major bleeding complications appeared in 14.3% of the patients with local thrombolysis and in 20.8% of the ones treated by systemic thrombolysis, without statistical significance. Moreover, the proportion of minor bleeding was comparable in the two groups of patients. There was no intracranial bleeding. Disseminated intravascular coagulation occurred in 1 patient with systemic thrombolysis.
CONCLUSIONS: The rate of clinical success and the regression of RV overload were significantly higher in patients treated by pulmonary intra-arterial thrombolysis. The results regarding the efficiency of the pulmonary intra-arterial thrombolysis in high-risk PE are encouraging, the mortality in these patients being significantly lower than the one for systemic administration of the thrombolytic agent.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25563712     DOI: 10.5603/CJ.a2014.0103

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  6 in total

1.  Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis.

Authors:  Ariel Izcovich; Juan M Criniti; Federico Popoff; Liming Lu; Jiaming Wu; Walter Ageno; Daniel M Witt; Michael R Jaff; Sam Schulman; Veena Manja; Peter Verhamme; Gabriel Rada; Yuqing Zhang; Robby Nieuwlaat; Wojtek Wiercioch; Holger J Schünemann; Ignacio Neumann
Journal:  Blood Adv       Date:  2020-04-14

Review 2.  Interventional radiology treatment for pulmonary embolism.

Authors:  Miguel A De Gregorio; Jose A Guirola; Celia Lahuerta; Carolina Serrano; Ana L Figueredo; William T Kuo
Journal:  World J Radiol       Date:  2017-07-28

Review 3.  Understanding haemorrhagic risk following thrombolytic therapy in patients with intermediate-risk and high-risk pulmonary embolism: a hypothesis paper.

Authors:  Paul Abraham; Diego A Arroyo; Raphael Giraud; Henri Bounameaux; Karim Bendjelid
Journal:  Open Heart       Date:  2018-02-26

4.  Local Thrombolysis in High-Risk Pulmonary Embolism-13 Years Single-Center Experience.

Authors:  Liviu Macovei; Razvan Mihai Presura; Robert Magopet; Cristina Prisecariu; Carmen Macovei; Gabriela Omete; Igor Nedelciuc; Mircea Balasanian
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

5.  American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.

Authors:  Thomas L Ortel; Ignacio Neumann; Walter Ageno; Rebecca Beyth; Nathan P Clark; Adam Cuker; Barbara A Hutten; Michael R Jaff; Veena Manja; Sam Schulman; Caitlin Thurston; Suresh Vedantham; Peter Verhamme; Daniel M Witt; Ivan D Florez; Ariel Izcovich; Robby Nieuwlaat; Stephanie Ross; Holger J Schünemann; Wojtek Wiercioch; Yuan Zhang; Yuqing Zhang
Journal:  Blood Adv       Date:  2020-10-13

6.  Role of Shear Stress and tPA Concentration in the Fibrinolytic Potential of Thrombi.

Authors:  Claire S Whyte; Hadj Ahmed Mostefai; Kim M Baeten; Andrew J Lucking; David E Newby; Nuala A Booth; Nicola J Mutch
Journal:  Int J Mol Sci       Date:  2021-02-20       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.